Accessibility Statement

Lilly Global Health Initiatives

  • UNICEF – In 2022, Lilly and UNICEF announced an initiative to improve health for 10 million children and adolescents living with or at risk of chronic NCDs through 2025. Lilly committed $14.4 million to UNICEF USA to support life-saving work to address NCD risk factors, strengthen health systems and enhance the ability of healthcare workers to care for people in Bangladesh, Malawi, Nepal, Zimbabwe and the Philippines. In 2024, Lilly expanded its charitable contribution to UNICEF USA by $6.54 million to include resource-limited settings in India and improve health for 6 million children and adolescents living with or at risk of chronic NCDs in India through 2030 along with $500,000 for implementation research projects. The selected countries have the potential to strengthen country-level health systems and models that provide care and support for children and adolescents with chronic conditions, including type 1 diabetes, congenital and rheumatic heart disease, sickle cell disease and chronic respiratory diseases (e.g., asthma). More than 6.6 million people have been reached through UNICEF’s work during 2024 including clinicians, community health workers, district trainers, caregivers, children and adolescents. *UNICEF does not endorse any company, brand, product, or service.

  • AMPATH (Academic Model Providing Access to Healthcare) – Lilly product donations to Catholic Medical Mission Board have supported the AMPATH Kenya initiative which totals to more than $255 million – including more than $4.3 million in medicines in 2024 – helping people living with cancer, diabetes and mental health disorders. Most recently, Lilly provided more than $3 million donation to Indiana University Foundation to support efforts related to the AMPATH México initiative The charitable initiative aims to transform primary healthcare for NCDs through training and deploying community health workers and early-career healthcare providers to address diabetes and related NCDs, with potential reach of over 3 million people in resource-limited settings by 2030.

  • Life for a Child – Since 2009, Lilly has provided over 10.6 million vials and cartridges of insulin related to support of the Life for a Child program. The program supports children and youth with diabetes in resource-limited settings by providing insulin, delivery devices, monitoring supplies, medical care, diabetes education, complications screening and management, and advocacy. In 2021, Lilly announced plans to expand support for Life for a Child, aiming to reach approximately 150,000 children and youth annually by 2030. To enable this, Lilly increased contributions of mealtime and basal insulins, reusable pens, and financial support for storage, packing, and shipping costs in collaboration with Direct Relief. In 2024, more than 53,000 children and youth were supported by Life for a Child with Lilly insulin.

  • CEO Round Table (CEORT) in-country programs: The rise of NCDs emphasizes the need for multi-sector engagement to strengthen health systems and integrated service delivery using digital tools. Alongside separate support provided by the Gates Foundation and industry peers engaged through CEORT programs, Lilly provides donations to US charitable organizations supporting the implementation of charitable programs on the ground in Sub-Saharan Africa:

    • AYA Integrated Healthcare Initiative (AYA): Lilly is donating nearly $3 million to Panorama Global related to its support of implementation of the AYA project in Ghana, which aims to improve NCD care at the primary health level. It includes training, guidelines, and digital tools to reach an estimated 2.2 million people in resource-limited settings.

    • Point of Care Ultrasound (POCUS): Lilly's $1.7 million donation to Panorama Global related to its support of the implementation of projects expanding POCUS capacity in Kenya for early diagnosis of NCDs like obstetrical complications, heart failure, and breast cancer, benefiting approximately 550,000 patients in resource-limited settings.

    • Digital Mentor: This project in Kenya aims to train 20,000 frontline workers using AI tools to improve CHW productivity. It is estimated to reach 5 million people in resource-limited settings. Lilly is donating $800,000 to Panorama Global to support the implementation of this project.

  • Growth Accelerator for Integrated NCD Services (GAINS): Lilly's $500,000 donation to Touch Health aims to support its deployment of 140,000 Community Healthcare Workers in Tanzania by 2028, enhancing primary healthcare access through integrated community services and digital health systems.

  • Cold Chain Initiative – In early 2023, Lilly and Direct Relief announced a new initiative to increase refrigeration capacity for insulin storage as well as other cold chain medicines in resource-limited settings in LMICs. With Lilly’s $1.15 million funding, Direct Relief procured and installed 151 refrigeration units across 18 countries for 82 Life for a Child partner facilities in Africa, Latin America, the Caribbean, and South Asia. In 2024, Lilly committed an additional $4.3 million funding to Direct Relief to allow it to purchase and install approximately 600 refrigeration units in Life for a Child partner facilities in Africa, Latin America, the Caribbean, the Middle East, and Asia.

  • Cities Taking Action for Gender Equity in Cancer Care – Lilly is supporting Global Focus on Cancer (GFC) in their charitable efforts related to addressing the critical gap in cancer care for women in 3 resource-limited cities: Tbilisi, Georgia; Nairobi, Kenya; and León, Mexico.

  • The Max Foundation Humanitarian PACT for Advanced Breast Cancer Program – In 2024, Lilly and The Max Foundation announced a new initiative to provide access to Verzenio for 200 advanced breast cancer patients in in resource-limited settings in Kenya. Lilly’s support includes providing product and $510,000 in support to The Max Foundation to establish the program infrastructure, implementation, and operations.

  • Action for Diabetes (A4D) – Lilly provides support to A4D to develop and roll out the HelloType1 online educational platform for the type 1 diabetes community in eight Southeast Asian countries. Additionally, A4D supports youth living with type 1 diabetes in Laos with Lilly provided human and analog insulins. In 2024, HelloType 1 was available in 5 countries engaging more than 40,000 platform users, and 71 youth were supported by A4D with Lilly provided insulins.

  • Obesity, Diabetes, Gestational Diabetes, Hypertension and Other Noncommunicable Diseases (NCDs)- Lilly supports the United States Mexico Foundation for Science (USMFS) with a $5 million donation over 4 years to support its charitable efforts related to addressing NCDs like obesity, diabetes and hypertension in resource-limited areas of Mexico. This initiative aims to improve health outcomes for 4.65 million people in resource-limited settings by 2030 through a Personalized Public Health Model in primary care, using the digital health ecosystem. More than 226,000 individuals were reached in 2024.

  • Expanding Comprehensive Diabetes Care Model across Mexico and U.S. – Lilly provided $1.67 million to Fundación por un Mexico sin Diabetes and Instituto Tecnológico Autónomo de México for a six-year effort to validate and expand a comprehensive diabetes care model for underserved patients with the goal of improving health long term. The efficacy of the model of care has been validated, and enabled Clinicas del Azúcar to grow to 49 clinics in Mexico and 1 clinic in the USA, benefiting over 420,000 and saving nearly $1.26 billion by preventing diabetes complications. In addition, Lilly is supporting Clinicas del Azúcar’s model for further expansion into the United States to provide low-cost, improved diabetes management and care with the potential to reach 1 million underserved patients by 2030 in Texas and other border states.

  • Diabetes Impact Project – Indianapolis Neighborhoods (DIP-IN) –Lilly committed $12 million to the DIP-IN project, focusing on three Indianapolis communities with high diabetes prevalence. Launched in 2018, DIP-IN aims at diabetes prevention and control. The project leverages resident steering committees to lead neighborhood-based health promotion initiatives, expanding access to health-supporting resources and improving overall health. It includes neighborhood- and clinic-based community health workers (CHWs) to identify people living with or at risk of developing diabetes and connect them to quality care. Led by Indiana University Richard M Fairbanks School of Public Health and other organizations, more than 788 people with diabetes have worked with DIP-IN CHWs, resulting in a significant reduction in HbA1c levels.

  • Direct Relief Fund for Health Equity – In 2021, Lilly committed $5 million over five years to Direct Relief’s Fund for Health Equity. This fund allows U.S. health centers, free and charitable clinics, other community-based organizations and educational institutions to apply for grants of up to $250,000 annually. Direct Relief makes grants to strengthen the capacity of recipient organizations to provide high-quality, culturally appropriate healthcare while focusing on social determinants of health for underserved populations. Lilly’s funding has supported 16 awardees who have reached more than 87,000 people to date.

See important information about our Sustainability report.